We present a 34-year-old patient with digital necrosis due to thromboangiitis obliterans. He was successfully treated with iloprost, a prostaglandin analogue. Duplex ultrasonography was performed during the perfusion of iloprost to optimize the doses and the treatment duration. A complete revascularization was observed after 10 days. Iloprost perfusions were stopped, and a slow regression of the necroses was observed in the subsequent days. With the use of duplex ultrasonography, unnecessary high doses of iloprost and long periods of treatment can be avoided reducing side effects and treatment costs.

Keywords:
Thromboangiitis obliterans, Iloprost, Duplex ultrasonography
1.
Cazalets C, Laurat E, Cador B, et al: Cannabis arteritis: Four new cases. Rev Méd Interne 2003;24:127–130.
2.
Disdier P, Granel B, Serratrice J, et al: Cannabis arteritis revisited – Ten new case reports. Angiology 2001;52:1–5.
3.
Noël B: Cardiovascular complications of cocaine use. N Engl J Med 2001;345:1575, author reply 1576.
4.
Fiessinger JN, Schafer M: Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans: The TAO Study. Lancet 1990;335:555–557.
5.
Noël B, Krayenbuhl B, Cerottini JP, et al: Thromboangiitis obliterans: A rare cause of a reversible Raynaud’s phenomenon. Dermatology 2000;200:363–365.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.